Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models

[en] With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve secondline therapy of SCLC. The effect of chemotherapeutic agents was evaluated in cell lines (apoptosis, reactive oxygen species, and RNA and protein expression) and in mouse models (tumour development). We demonstrate here that valproic acid, a histone deacetylase inhibitor, improves the efficacy of a second-line regimen (vindesine, doxorubicin and cyclophosphamide) in SCLC cells and in mouse models. Transcriptomic profiling integrating microRNA and mRNA data identifies key signalling pathways in the response of SCLC cells to valproic acid, opening new prospects for improved therapies.

Disciplines :

Oncology

Author, co-author :

Hubaux, Roland

Vandermeers, Fabian

Cosse, Jean-Philippe

Crisanti, Cecilia

Kapoor, Veena

Albelda, Steven M.

Mascaux, Céline

Delvenne, Philippe

Hubert, Pascale

Willems, Luc ; Université de Liège > Agronomie, Bio-ingénierie et Chimie (AgroBioChem) > Biologie cell. et moléc.

Language :

English

Title :

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models

Publication date :

19 October 2015

Journal title :

ERJ Open Research

eISSN :

2312-0541

Publisher :

European Respiratory Society, Sheffield, United Kingdom

Volume :

Issue :

Pages :

00028

Peer reviewed :

Peer Reviewed verified by ORBi

Name of the research project :

The Interuniversity Attraction Poles programme BELVIR initiated by the Belgian Science Policy Office
The Action de Recherche Concertée Glyvir of the Communauté française de Belgique
Synbiofor
Agricultureislife
The Plan Cancer of the Service Public Fédéral

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique
Télévie
BELSPO - Belgian Science Policy Office
CFB - Communauté française de Belgique
Belgian Foundation Against Cancer
NEDO - New Energy and Industrial Technology Development Organization
SPW DGO6 - Service Public de Wallonie. Economie, Emploi, Recherche
CAC - Centre anticancéreux près l'Université de Liège asbl
ULiège. GxABT - Liège Université. Gembloux Agro-Bio Tech
ULg FSR - Université de Liège. Fonds spéciaux pour la recherche

Funding text :

The Partenariat Public Privé INCA of the Direction générale des Technologies, de la Recherche et de l’Energie/DG06 of the Walloon government

Available on ORBi :

since 12 January 2016

Statistics

Number of views

53 (2 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Amini A, Byers LA, Welsh JW, et al. Progress in the management of limited-stage small cell lung cancer. Cancer 2014; 120: 790-798.
Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010; 35: 202-215.
Oze I, Hotta K, Kiura K, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009; 4: e7835.
Rossi A, Maione P, Palazzolo G, et al. New targeted therapies and small-cell lung cancer. Clin Lung Cancer 2008; 9: 271-279.
Osterlind K. Chemotherapy in small cell lung cancer. Eur Respir J 2001; 18: 1026-1043.
Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25: 552-563.
Petta V, Gkiozos I, Strimpakos A, et al. Histones and lung cancer: are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol 2013; 72: 935-952.
Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004; 46: 171-178.
Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008; 14: 188-198.
Leclercq S, Gueugnon F, Boutin B, et al. A 5-aza-2´-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur Respir J 2011; 38: 1105-1116.
Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011; 37: 129-135.
Chapman A, Keane PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982; 19: 315-359.
Cinatl J, Jr., Cinatl J, Scholz M, et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 1996; 7: 766-773.
DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003; 37: Suppl. 2, 25-42.
Bouzar AB, Boxus M, Defoiche J, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 41-52.
Crisanti MC, Wallace AF, Kapoor V, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009; 8: 2221-2231.
Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34: 206-222.
Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978.
Hubaux R, Vandermeers F, Crisanti MC, et al. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer 2010; 46: 1724-1734.
Vandermeers F, Hubert P, Delvenne P, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009; 15: 2818-2828.
Achachi A, Florins A, Gillet N, et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci USA 2005; 102: 10309-10314.
Hubaux R, Thu KL, Coe BP, et al. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation. J Thorac Oncol 2013; 8: 1102-1106.
Spiller HA, Krenzelok EP, Klein-Schwartz W, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol 2000; 38: 755-760.
Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-1281.
Suzuki H, Maruyama R, Yamamoto E, et al. Epigenetic alteration and microRNA dysregulation in cancer. Front Genet 2013; 4: 258.
Berghmans T, Lafitte J-J, Scherpereel A, et al. VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ Open Res 2015; 1: 00029-2015.
Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010; 75: 173-234.
Zhang Y, Xing D, Liu L. PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-X L during UV-induced apoptosis. Mol Biol Cell 2009; 20: 3077-3087.
Zhang K, Zhang H, Zhou X, et al. miRNA589 regulates epithelial-mesenchymal transition in human peritoneal mesothelial cells. J Biomed Biotechnol 2012; 2012: 673096.
Wang H, Yan C, Shi X, et al. MicroRNA-575 targets BLID to promote growth and invasion of non-small cell lung cancer cells. FEBS Lett 2015; 589: 805-811.
Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432: 635-639.
Tanaka S, Akiyoshi T, Mori M, et al. A novel frizzled gene identified in human esophageal carcinoma mediates APC/β-catenin signals. Proc Natl Acad Sci USA 1998; 95: 10164-10169.
Ueno K, Hiura M, Suehiro Y, et al. Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 2008; 10: 697-705.
Hubaux R, Thu KL, Lam WL. Re: the Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 2014; 106.
Calvo R, West J, Franklin W, et al. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA 2000; 97: 12776-12781.
Coe BP, Lockwood WW, Girard L, et al. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 2006; 94: 1927-1935.
Park K-S, Lim J, Singh A, et al. The tumor suppressor role of Wnt/β-catenin pathway in small cell lung cancer. Am J Respir Crit Care Med 2012; 185: A5539.
Bordonaro M, Lazarova DL, Sartorelli AC. Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer? Oncol Res 2008; 17: 1-9.
Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
Cai Y, Mohseny AB, Karperien M, et al. Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010; 220: 24-33.